This clinical trial is focused on studying a type of prostate cancer known as Metastatic Castration-resistant Prostate Cancer. This is a form of prostate cancer that continues to grow and spread even when the amount of testosterone in the body is reduced to very low levels. The study is testing a new treatment called Vobramitamab Duocarmazine, which is an antibody-drug conjugate. This means it is a special type of medicine that combines an antibody with a drug to target and kill cancer cells more effectively. The trial will also use a medication called Prednisone, which is a steroid that can help reduce inflammation and support the body during cancer treatment.

The purpose of the study is to evaluate how effective Vobramitamab Duocarmazine is at two different dose levels in treating this type of prostate cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will compare the effects of the two dose levels to see which one works better in slowing down the progression of the cancer. Some participants may also receive a placebo, which is a substance with no active medication, to help researchers understand the true effects of the treatment.

Throughout the study, participants will be monitored regularly to assess how the cancer is responding to the treatment. This will involve various tests and scans, such as MRI or computed tomography (CT), to check for changes in the cancer. The study aims to provide valuable information on the potential benefits and safety of Vobramitamab Duocarmazine for patients with this challenging form of prostate cancer. The trial is expected to continue for a period of time to gather enough data to make informed conclusions about the treatment’s effectiveness.